Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

M7824

EU flag

Imbruvica wins wider European leukaemia licence

AbbVie and J&J’s first-in-class drug now approved to treat all CLL patients in the EU

- PMLiVE

Merck agrees African digital cooperation deal

Will collaborate with Germany's GIZ on new solutions for the continent

- PMLiVE

Women’s well-being needs are broader than health

Merck event hears how women’s and government priorities are often mismatched

- PMLiVE

FDA clears Imbruvica as chemo alternative for first-line CLL

Johnson & Johnson/AbbVie's first-in-class drug now approved for all CLL patients

- PMLiVE

UK government fines GSK over ‘pay-for-delay’ deals

Merck KGaA and Actavis also fined for their involvement

- PMLiVE

Merck’s digital health accelerator expands into Africa

Will run new startup support programme in Nairobi

- PMLiVE

Merck KGaA adds two to its executive board

Appoints Udit Batra and Walter Galinat, while Bernd Reckmann will retire

- PMLiVE

Germany’s Merck triumphs in court battle with US namesake

English court rules Merck & Co breached the firms' naming agreement

- PMLiVE

Syndax teams with Merck/Pfizer on immuno-oncology combo

Oral cancer drug entinostat to test with avelumab

- PMLiVE

Merck abandons evofosfamide as two trials fail

Solid tumour candidate underwhelms in phase III studies

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links